The central role of the IFN-γ/chemokine axis in driving vitiligo, requiring activation of JAK1/JAK2, provided the rationale for highly successful treatment of the disease using JAK inhibitors, both orally and topically (Table 1) (69). Here, IFNG is linked to vitiligo.